Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

SIMPLE SUMMARY: The emergence of new therapeutic agents for multiple myeloma (MM) over the last 2 decades has resulted in a significant improvement in overall survival (OS). However, this improvement might be associated with the increased incidence of second primary malignancies (SPMs). Most studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Avivi, Irit, Vesole, David H., Davila-Valls, Julio, Usnarska-Zubkiewicz, Lidia, Olszewska-Szopa, Magdalena, Milunovic, Vibor, Baumert, Bartłomiej, Osękowska, Bogumiła, Kopińska, Anna, Gentile, Massimo, Puertas-Martinez, Borja, Robak, Paweł, Crusoe, Edvan, Rodriguez-Lobato, Luis Gerardo, Gajewska, Małgorzata, Varga, Gergely, Delforge, Michel, Cohen, Yael, Gozzetti, Alessandro, Pena, Camila, Shustik, Chaim, Mikala, Gabor, Zalac, Klara, Alexander, H. Denis, Barth, Peter, Weisel, Katja, Martínez-López, Joaquín, Waszczuk-Gajda, Anna, Krzystański, Mateusz, Jurczyszyn, Artur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487060/
https://www.ncbi.nlm.nih.gov/pubmed/37686635
http://dx.doi.org/10.3390/cancers15174359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487060/
https://www.ncbi.nlm.nih.gov/pubmed/37686635
http://dx.doi.org/10.3390/cancers15174359

Ejemplares similares